Search results
Results from the WOW.Com Content Network
The Bethesda system (TBS), officially called The Bethesda System for Reporting Cervical Cytology, is a system for reporting cervical or vaginal cytologic diagnoses, [1] used for reporting Pap smear results. It was introduced in 1988 [2] and revised in 1991, [3] 2001, [1] [4] [5] and 2014. [6]
The Bethesda System for Reporting Thyroid ... Suspicious for malignancy: ... Only a small percentage of lumps in the neck are malignant (around 4 – 6.5% ...
Histopathology of NIFTP, H&E stain. [1]Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an indolent thyroid tumor that was previously classified as an encapsulated follicular variant of papillary thyroid carcinoma, [2] necessitating a new classification as it was recognized that encapsulated tumors without invasion have an indolent behavior, [2] and may ...
The overall 5-year survival rate for follicular thyroid cancer is 91%, and the 10-year survival rate is 85%. [8] By overall cancer staging into stages I to IV, follicular thyroid cancer has a 5-year survival rate of 100% for stages I and II, 71% for stage III, and 50% for stage IV. [9]
Hürthle cell neoplasms can be separated into Hürthle cell adenomas (benign tumours) and carcinomas (malignant tumours) [5] arising from the follicular epithelium of the thyroid gland. [6] The latter is a relatively rare form of differentiated thyroid cancer, accounting for only 3-10% of all differentiated thyroid cancers, [ 7 ] and was ...
The prognosis of thyroid cancer is related to the type of cancer and the stage at the time of diagnosis. For the most common form of thyroid cancer, papillary, the overall prognosis is excellent with 97%, 95%, and 90% 10, 15 and 20 year overall survival respectively. [58] The 5 year survival of all thyroid cancers, with treatment, is 98%. [10]
Relative incidences of malignant thyroid tumors, with Hürthle cell carcinoma near top right. Hürthle cell neoplasm is a rare tumor of the thyroid, typically seen in women between the ages of 70 and 80 years old. When benign, it is called a Hürthle cell adenoma, and when malignant it is called a Hürthle cell carcinoma.
The Amsterdam criteria arose as a result of a meeting of the International Collaborative Group on Hereditary Non-Polyposis Colon Cancer in Amsterdam, in 1990. [5] Following this, some of the genetic mechanisms underlying Lynch syndrome were elucidated during the 1990s and the significance of tumours outside the colon , such as those of the ...